Company: PGEN
Filing Date: 2025-03-19
Form Type: 10-K
Source: 0001356090-25-000007
Chunk: 199

Company: PRECIGEN, INC.
Filing Date: 2025-03-19
Form: 10-K
Item: Item 12
Chunk 199
---
 under the 2019 Plan, of which 3,686,048 stock options and 826,057 RSUs were outstanding, and 2,448,058 shares were available for grant.Stock OptionsStock options may be granted with an exercise price equal to or greater than the stock's fair market value at the date of grant. Stock options may be granted with an exercise price less than the stock's fair market value at the date of grant only if the stock options are replacement options in accordance with certain United States Treasury regulations. All stock options have terms of up to ten-year and vest four years from the date of grant.Stock option activity was as follows:Number of SharesWeighted Average Exercise PriceWeighted Average Remaining Contractual Term (Years)Balances at December 31, 202112,260,187 $14.06 6.79Granted4,451,890 2.22 Exercised(375)(2.28)Forfeited(567,179)(5.19)Expired(943,247)(22.32)Balances at December 31, 202215,201,276 10.41 6.87Granted7,847,869 1.19 Exercised— — Forfeited(275,250)(2.65)Expired(716,555)(20.41)Balances at December 31, 202322,057,340 6.90 7.12Granted7,361,674 1.40 Exercised(265,448)(1.30)Forfeited(1,586,732)(1.72)Expired(1,642,100)(17.10)Balances at December 31, 202425,924,734 5.07 7.05Exercisable at December 31, 202415,384,119 7.42 5.89Total unrecognized compensation costs related to unvested awards as of December 31, 2024 were $10,135 and are expected to be recognized over a weighted-average period of approximately 2.5 years.The weighted average grant date fair value of options granted during 2024, 2023, and 2022 was $1.12, $0.92, and $1.65, respectively. The aggregate intrinsic value of options exercised during 2024, 2023, and 2022 was $60, $0, and $0, respectively.